Genomics Market Size & Share 2026-2035

Genomics Market Size

The genomics market was valued at USD 44.7 billion in 2025 and is projected to increase from USD 51.2 billion in 2026 to USD 188.7 billion by 2035, expanding at a 15.6% CAGR, reflects the shift of genomic analysis from specialist research into clinical diagnosis, biomarker-led development, and population-health infrastructure.

Lower sequence-generation costs have widened the set of workflows that can support genomic testing, while national programs are converting episodic research demand into recurrent procurement. England's NHS Genomic Medicine Service delivered more than 810,000 genomic tests in 2024, and the NIH All of Us program's February 2025 release included genomic data from more than 633,000 participants ^{[1]NHS England, england.nhs.uk}, ^{[2]All of Us Research Program / NIH, researchallofus.org}. The resulting demand extends beyond sequencers: it requires sample preparation, recurring reagents, validated interpretation, and secure computing.

Products account for USD 29,894.7 million in 2025, but their economics are increasingly shaped by utilization after instrument placement. Consumables and reagents represent USD 18,548.4 million of that total and are projected to reach USD 73,159.2 million by 2035. Services are forecast to grow faster, at 16.2%, as laboratories and drug developers procure sequencing, bioinformatics, and biomarker translation as integrated workflows. The five leading suppliers-Illumina, Thermo Fisher Scientific, Agilent Technologies, BGI Genomics, and F. Hoffmann-La Roche-collectively hold approximately 70.1% of the 2025 market.

Key Drivers

Rising Prevalence of Genetic and Chronic Diseases

Cancer, inherited disorders, and chronic disease management are increasing the clinical relevance of genomic information. Rare conditions frequently require broad sequencing because symptom-led testing can leave patients without a diagnosis for years. Population datasets add another demand channel by linking variants to phenotypes; the NIH reported more than 275 million previously unreported variants in an All of Us release ^{[3]NIH, nih.gov}. As variant knowledge expands, laboratories require recurring analytical updates rather than one-time sequencing capacity.

Population-specific reference resources matter commercially because variant interpretation is less reliable when databases underrepresent the population being tested. Saudi Arabia's program has sequenced more than 63,000 samples, while the first fully annotated diploid Saudi genome and a Saudi pangenome improve the regional reference base ^{[4]Saudi Vision 2030, vision2030.gov.sa}. Such programs support demand for sequencing and informatics, but their clinical impact depends on translation into validated local testing pathways.

Advancements in DNA Sequencing and Gene Editing Technologies

Genome sequencing costs have fallen from roughly USD 100 million in 2001 to about USD 500 in 2023. Illumina positions the NovaSeq X at a USD 200 genome cost on 25B flow cells at list price. Cost compression expands cohort size and testing frequency, yet it does not eliminate the cost of library preparation, analysis, storage, interpretation, or clinical reporting.

Long-read platforms address gaps left by short reads in structural variation, repeat regions, and epigenetic analysis. Oxford Nanopore reported 55.8% underlying constant-currency growth for its PromethION range in 2024, while PacBio's Revio advances target lower-cost high-accuracy long-read genomes. These systems are not simply substitutes for high-throughput short-read sequencing; they enlarge the addressable workflow where complex genomic architecture affects diagnosis or biological discovery.

Gene editing also creates downstream sequencing demand. Editing programs need genomic target selection and validation of on-target and off-target outcomes. Meanwhile, NVIDIA's January 2025 genomics collaborations with Illumina, Arc Institute, IQVIA, and Mayo Clinic demonstrate the growing role of accelerated computing in multiomic analysis and drug discovery.

Increasing Adoption of Precision Medicine

Precision medicine changes the purchasing model from research-led sequencing to repeated clinical use. The NHS service operates through seven Genomic Laboratory Hubs and delivered more than 810,000 tests in 2024. Its Generation Study began offering whole-genome sequencing for more than 200 treatable rare conditions through 13 NHS hospitals in October 2024. Such centralized networks can concentrate specialist interpretation and standardize procurement while widening access through clinical referral pathways.

Germany's genomeDE program provides a contrasting route: a EUR 700 million, five-year pilot for rare and oncological disease sequencing that moved into implementation in July 2024. In India, Illumina has identified sequencing utilization as a fast-growing opportunity, supported by clinical demand and population-genomics initiatives. The common commercial requirement is not merely access to sequencers but a durable payment, data-governance, and clinical-validation model.

Government Initiatives and Funding for Genomics Research

Government programs create demand by funding equipment, data platforms, workforce capability, and clinical adoption together. All of Us is building a large U.S. genomic and health-record resource, while Genome UK's implementation plan sets out the policy framework for embedding genomics in health services. In Europe, cross-border initiatives create demand for interoperable infrastructure but also raise requirements for secure access and common standards.

Saudi Arabia's SGP 2.0 combines a national genomics agenda with investments in sequencing, CRISPR, and AI-enabled analysis. These programs can accelerate market formation where domestic research, clinical demand, and procurement are coordinated. They are less likely to produce sustained volumes where funding covers instruments but not long-term interpretation, clinical integration, or data stewardship.

Key Restraints

Ethical and Privacy Concerns around Genetic Data

Genetic data can reveal information about relatives as well as the individual tested, making consent, reuse, and cross-border sharing operational constraints rather than peripheral compliance issues. The EU classifies genetic data as a special category under GDPR. Germany's genomeDE design separates clinical and genomic data and uses a trust-center model for pseudonymization, illustrating how privacy requirements shape system architecture and operating cost ^{[5]Nature Medicine, nature.com}.

Public acceptance is equally material. National-scale programs depend on clear consent, return-of-results policies, and credible governance. Where those controls are weak, enrollment and data-sharing may lag even when sequencing hardware is available. Restrictions around human genetic resources can also limit multinational study designs and complicate the creation of diverse reference datasets.

High Cost and Affordability Issues

A low sequencing consumable price is not the same as an affordable clinical test. The USD 200 figure for high-throughput sequencing excludes sample preparation, quality control, data storage, interpretation, reporting, and the workforce required to act on a result. These costs are particularly restrictive where reimbursement is absent or clinical genomic expertise is scarce.

Capital equipment introduces a second barrier. Laboratories may respond through centralization or outsourced services, but those approaches can create specimen logistics, turnaround-time, and data-transfer constraints. Switching platforms can also require assay revalidation, staff training, and software reconfiguration. Consequently, lower-cost entrants can face slower adoption than their run-level economics suggest.

Genomics Market Segment Analysis

By Type

Products generate USD 29,894.7 million in 2025 and are projected to reach USD 122,708.3 million by 2035 at a 15.3% CAGR. Instruments account for USD 11,346.3 million in 2025 and grow at 16.0%, supported by replacement cycles and new laboratory capacity. Consumables and reagents, at USD 18,548.4 million, reach USD 73,159.2 million by 2035. Their recurring use makes installed-base utilization more important to suppliers than initial placement alone. Illumina's 2024 consumables revenue was USD 2.87 billion, or 66% of its total revenue, illustrating this revenue model ^{[6]Illumina, Inc., investor.illumina.com}.

Services rise from USD 14,770.8 million to USD 65,945.3 million at a 16.2% CAGR. NGS-based services grow from USD 5,915.6 million to USD 26,118.8 million; core genomics services from USD 3,415.4 million to USD 15,880.3 million; biomarker translation services from USD 1,849.5 million to USD 8,748.7 million; computational services from USD 2,740.8 million to USD 11,689.5 million; and other services from USD 849.4 million to USD 3,508.1 million. Biomarker translation has the highest service CAGR, 16.9%, because drug developers need validated evidence and analysis, not only raw sequence output.

By Technology

PCR grows from USD 14,219.0 million in 2025 to USD 62,780.8 million by 2035 at 16.1%, supported by its role in routine detection and quantitative workflows. Sequencing remains the largest technology segment, rising from USD 16,967.3 million to USD 70,729.9 million at 15.4%. The two technologies serve different workflow needs: PCR can provide fast, targeted measurement, while sequencing discovers or characterizes broader genomic variation.

Microarray advances from USD 5,016.8 million to USD 21,459.1 million at 15.7%. It remains useful for high-volume analysis of known variants, even as sequencing expands. Nucleic acid extraction and purification grows from USD 5,852.6 million to USD 23,877.2 million at 15.2%; sample quality is an upstream determinant of downstream assay performance. QIAGEN's Sample Technologies sales were USD 642.0 million in 2024 ^{[7]QIAGEN, s28.q4cdn.com}. Other technologies rise from USD 2,609.8 million to USD 9,806.6 million at 14.2%, including specialized approaches such as FISH and spatial genomics.

By Application

Diagnostics is the leading application, at USD 15.8 billion in 2025. Its scale reflects oncology profiling, rare-disease testing, prenatal and newborn screening, pharmacogenomics, and surveillance. Clinical workflows favor suppliers that can demonstrate reproducibility, reporting quality, and compatibility with hospital operations. Drug discovery and development is projected to reach USD 54.5 billion by 2035, driven by target discovery, biomarker selection, and patient stratification.

Precision medicine links these applications to individual care pathways. Agriculture and animal research uses genomic selection and trait analysis, while other applications include reproductive health, forensics, ancestry, and environmental genomics. These smaller applications diversify demand but generally require distinct reference data, regulatory practices, and sample workflows.

By End Use

Hospitals and clinics are adopting genomics through oncology, rare-disease, and screening pathways, often using centralized laboratory networks. Research centers and academic and government institutes continue to underpin methods development and population datasets. Pharmaceutical and biotechnology companies lead end-use demand in 2025 and are projected to reach USD 68.9 billion by 2035, reflecting genomics' role in discovery, clinical trials, companion diagnostics, and regulatory evidence.

Other end users include contract research organizations, forensic laboratories, agricultural genomics providers, and direct-to-consumer testing companies. Their procurement is typically more application-specific, creating opportunities for service providers and workflow specialists rather than a single uniform platform model.

Genomics Market Regional Analysis

North America

North America is valued at USD 19,070.2 million in 2025, representing 42.7% of the global market, and is projected to reach USD 81,507.0 million by 2035 at a 15.7% CAGR. The United States contributes USD 17,339.2 million, or 90.9% of the regional total, and is projected to reach USD 74,393.0 million. Its historical market expanded from USD 11.5 billion in 2022 to USD 15.1 billion in 2024. The combination of pharmaceutical demand, federal research infrastructure, and clinical testing channels supports recurring reagent and service demand. Canada contributes USD 1,731.0 million in 2025 and is projected to reach USD 7,114.0 million.

Europe

Europe reaches USD 12,615.5 million in 2025 and is forecast to reach USD 50,931.4 million by 2035 at 15.1%. The UK's NHS Genomic Medicine Service provides an established delivery model, while Germany's genomeDE program ties clinical sequencing to a national implementation and data-governance framework. France, Spain, Italy, the Netherlands, and other European markets add demand through hospital systems, research networks, and national programs. The region's procurement environment rewards suppliers able to meet interoperability, data-protection, and evidence expectations.

Asia Pacific

Asia Pacific is the fastest-growing region, increasing from USD 10,109.5 million in 2025 to USD 44,528.9 million in 2035 at 16.1%. China combines domestic platform capacity with a large clinical and research base; BGI Genomics reported RMB 3.87 billion in 2024 revenue, down 11% amid normalization of COVID-related contracts ^{[8]GenomeWeb, genomeweb.com}. Japan's cancer genomics infrastructure, India's clinical and population-genomics demand, Australia's rare-disease programs, and South Korea's precision-medicine initiatives provide separate growth channels. India's high growth potential is linked to expanding utilization rather than a mature installed base.

Latin America

Latin America rises from USD 1,905.2 million in 2025 to USD 7,880.4 million in 2035 at a 15.3% CAGR. Brazil is the largest market, supported by biomedical research and precision-medicine infrastructure. Mexico and Argentina contribute through hospital-based testing and research institutions. The region's ability to convert interest into sustained volumes will depend on reimbursement, reference-laboratory access, and local clinical-genetics capacity.

Middle East & Africa

Middle East & Africa grows from USD 965.1 million in 2025 to USD 3,806.0 million by 2035 at 14.8%. Saudi Arabia and the UAE are the principal Gulf demand centers, with Saudi national initiatives building local reference data and research capacity. In Africa, genomic surveillance and research networks provide important capability, but constrained infrastructure and workforce availability limit near-term clinical scale. The region therefore presents a split opportunity: Gulf programs can support concentrated, high-value procurement, while broader African adoption depends on service models and capacity building.

Genomics Market Share & Competitive Landscape

The market is concentrated among large platform and workflow suppliers, with the top five companies holding approximately 70.1% in 2025. Competitive advantage depends on installed base, consumables pull-through, regulatory and clinical workflow integration, and the ability to connect biological data to actionable analysis.

Agilent Technologies supplies SureSelect target-enrichment products, automated NGS preparation, microarray platforms, and cytogenomics tools. Its SureSelect XT HS workflow supports low-input FFPE applications and molecular barcoding for sensitive variant detection.

BGI Genomics combines DNBSEQ platforms, sequencing services, and international partnerships. Its competitive position rests on high-throughput cost positioning, although geographic concentration and regulatory scrutiny create execution risk.

Bio-Rad Laboratories is a major digital droplet PCR supplier. Its droplet-partitioning workflows support absolute nucleic-acid quantification in applications such as rare-mutation detection and liquid biopsy.

Color Genomics provides hereditary cancer testing, pharmacogenomic interpretation, and program design for health systems and employers. Its model emphasizes patient engagement and clinical implementation alongside testing.

Danaher participates through Integrated DNA Technologies, Cepheid, Beckman Coulter Life Sciences, and other operating companies. Custom oligonucleotides, CRISPR guide RNAs, library-preparation products, and automation position the company upstream of multiple genomic workflows.

Eppendorf supplies thermal cyclers, liquid handling, centrifuges, and laboratory consumables. Its role is enabling reproducible sample preparation and PCR workflows rather than competing directly in sequencing platforms.

Eurofins Scientific provides global laboratory services spanning sequencing, genotyping, NIPT, pharmacogenomics, gene synthesis, and agricultural genomics. Its network model addresses customers that require outsourced capacity and geographic reach.

F. Hoffmann-La Roche combines molecular diagnostics, genomic tumor profiling through Foundation Medicine, and oncology capabilities. Its Diagnostics Division generated CHF 14.324 billion in 2024. The company's integrated diagnostics-pharma position is particularly relevant to companion diagnostic workflows.

Illumina remains a central sequencing-platform supplier. Fiscal 2024 revenue was USD 4.33 billion, with USD 2.87 billion from consumables. NovaSeq X economics and the company's DRAGEN and Connected Analytics offerings link instruments to informatics; its collaboration with NVIDIA extends that stack into accelerated multiomic analysis.

Myriad Genetics focuses on hereditary cancer, pharmacogenomics, prenatal testing, and companion diagnostics. Its clinical model pairs complex laboratory testing with interpretation and counseling-oriented support.

NVIDIA is becoming a genomics infrastructure partner through accelerated computing, BioNeMo, RAPIDS, and collaborations with genomics and healthcare organizations. Its influence lies in the computational layer rather than sequence generation.

Oxford Nanopore Technologies competes through nanopore long-read sequencing, real-time analysis, and direct RNA and epigenetic detection. Its 2024 results showed 23.3% underlying constant-currency revenue growth and strong PromethION-range growth.

Pacific Biosciences of California supplies high-accuracy HiFi long-read sequencing. Its Revio strategy seeks to make structural-variant and phased-genome analysis viable for larger cohorts through lower per-genome costs.

QIAGEN provides sample preparation, molecular diagnostics, digital PCR, and NGS workflow products. Its 2024 net sales were USD 1.978 billion, including USD 642.0 million in Sample Technologies.

Quest Diagnostics provides clinical genetic and genomic testing through a large U.S. laboratory network. Its value proposition centers on physician access, ordering infrastructure, and reimbursement execution.

Thermo Fisher Scientific spans Ion Torrent sequencing, Applied Biosystems PCR, sample preparation, and life-science consumables. The company reported USD 42.88 billion in 2024 revenue, reflecting the breadth of the platform from which it serves genomics customers ^{[9]Thermo Fisher Scientific, ir.thermofisher.com}.

Recent Industry Developments

• January 13, 2025 - NVIDIA and Illumina announced a collaboration to combine NVIDIA accelerated computing and AI software with Illumina's multiomic data and DRAGEN analysis capabilities. The arrangement is intended to support multiomic analysis, biological foundation models, and pharmaceutical research workflows.
• February 5, 2025 - PT Naleya Genomik Indonesia, BGI Genomics' Indonesian joint venture, entered a research collaboration with Indonesia's national women's and children's health center on prenatal genomic screening. The initiative focuses on localized extended NIPT and CNV sequencing aligned with health-system priorities.
• March 4, 2025 - Oxford Nanopore reported 2024 annual results, including 55.8% underlying constant-currency growth for the PromethION range. The company linked the performance to adoption across human genetics, clinical research, biopharma, and applied markets.
• 2024-2025 - Oxford Nanopore launched PromethION 2 Integrated into open early access. The benchtop system combines two independent flow-cell positions with onboard compute for real-time analysis, targeting laboratories that need high-output long-read sequencing without separate computing infrastructure.
• March 2025 - Agilent continued expanding its SureSelect target-enrichment workflow for clinical research sequencing, building on low-input FFPE and molecular-barcoding capabilities. The development supports oncology panels, hereditary-disease testing, and comprehensive genomic profiling workflows.